Thiết kế hợp lý một yếu tố VIII PEGylated hoạt động hoàn toàn và có tác dụng kéo dài cho điều trị bệnh máu khó đông loại A

Vehar, 1984, Structure of human factor VIII., Nature, 312, 337, 10.1038/312337a0

Lillicrap, 2008, Extending half-life in coagulation factors: where do we stand?, Thromb Res, 122, S2, 10.1016/S0049-3848(08)70027-6

Björkman, 2001, Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia., Clin Pharmacokinet, 40, 815, 10.2165/00003088-200140110-00003

Björkman, 2009, Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A., Eur J Clin Pharmacol, 65, 989, 10.1007/s00228-009-0676-x

Lenting, 1999, The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein., J Biol Chem, 274, 23734, 10.1074/jbc.274.34.23734

Saenko, 1999, Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism., J Biol Chem, 274, 37685, 10.1074/jbc.274.53.37685

Bovenschen, 2003, Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII., J Biol Chem, 278, 9370, 10.1074/jbc.M212053200

Bovenschen, 2005, LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo., Blood, 106, 906, 10.1182/blood-2004-11-4230

Sarafanov, 2001, Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein., J Biol Chem, 276, 11970, 10.1074/jbc.M008046200

Bovenschen, 2005, The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor., J Thromb Haemost, 3, 1257, 10.1111/j.1538-7836.2005.01389.x

Tuddenham, 1982, Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease., Br J Haematol, 52, 259, 10.1111/j.1365-2141.1982.tb03888.x

Schwarz, 2002, Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease., Semin Thromb Hemost, 28, 215, 10.1055/s-2002-27823

Weiss, 1977, Stabilization of factor VIII in plasma by the von Willebrand factor: studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease., J Clin Invest, 60, 390, 10.1172/JCI108788

Veronese, 2008, The impact of PEGylation on biological therapies., Biodrugs, 22, 315, 10.2165/00063030-200822050-00004

Bailon, 2009, PEG-modified biopharmaceuticals., Expert Opin Drug Deliv, 6, 1, 10.1517/17425240802650568

Fishburn, 2008, The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics., J Pharm Sci, 97, 4167, 10.1002/jps.21278

Roberts, 2002, Chemistry for peptide and protein PEGylation., Adv Drug Deliv Rev, 54, 459, 10.1016/S0169-409X(02)00022-4

Röstin, 2000, B-domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol., Bioconjug Chem, 11, 387, 10.1021/bc990137i

McMullen, 1995, Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A)., Protein Sci, 4, 740, 10.1002/pro.5560040413

Stoilova-McPhie, 2002, 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography., Blood, 99, 1215, 10.1182/blood.V99.4.1215

Ngo, 2008, Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex., Structure, 16, 597, 10.1016/j.str.2008.03.001

Shen, 2008, The tertiary structure and domain organization of coagulation factor VIII., Blood, 111, 1240, 10.1182/blood-2007-08-109918

Lind, 1995, Novel forms of B-domain-deleted recombinant factor VIII molecules., Eur J Biochem, 232, 19, 10.1111/j.1432-1033.1995.tb20776.x

Cho, 2003, Versatile expression system for rapid and stable production of recombinant proteins., Biotechnol Prog, 19, 229, 10.1021/bp0255964

Cho, 2002, Establishment of a human somatic hybrid cell line for recombinant protein production., J Biomed Sci, 9631

Bi, 1995, Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A., Nat Genet, 10, 119, 10.1038/ng0595-119

Denis, 1998, A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis., Proc Natl Acad Sci U S A, 95, 9524, 10.1073/pnas.95.16.9524

Pan, 2009, Enhanced efficacy of recombinant FVIII in non-covalent complex with PEGylated liposome in hemophilia A mice., Blood, 114, 2802, 10.1182/blood-2009-03-212423

Terraube, 2009, Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance., Haemophilia, 2009, 1

Ganz, 1991, Definition of the affinity of binding between human von Willebrand factor and coagulation factor VIII., Biochem Biophys Res Commun, 180, 231, 10.1016/S0006-291X(05)81281-1

Vlot, 1995, The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor., Blood, 85, 3150, 10.1182/blood.V85.11.3150.bloodjournal85113150

Sandberg, 2001, Structural and functional characteristics of the B-domain deleted recombinant factor VIII protein, r-VIII SQ., Thromb Haemost, 85, 93, 10.1055/s-0037-1612910

Ananyeva, 2004, Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives., Blood Coagul Fibrinolysis, 15, 109, 10.1097/00001721-200403000-00001

Shima, 2006, Characterization of factor VIII inhibitors., Int J Hematol, 83, 109, 10.1532/IJH97.05160

Healey, 1995, Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII., J Biol Chem, 270, 14505, 10.1074/jbc.270.24.14505

Lollar, 1994, Inhibition of human factor VIIIa by anti-A2 subunit antibodies., J Clin Invest, 93, 2497, 10.1172/JCI117259

Ansong, 2006, Epitope mapping factor VIII A2 domain by affinity-directed mass spectrometry: residues 497-510 and 584-593 comprise a discontinuous epitope for the monoclonal antibody R8B12., J Thromb Haemost, 4, 842, 10.1111/j.1538-7836.2006.01831.x

Ahmad, 2005, Role of the C2 domain of factor VIIIa in the assembly of factor-X activating complex on the platelet membrane., Biochemistry, 44, 13858, 10.1021/bi0511033

Gaberc-Porekar, 2008, Obstacles and pitfalls in the PEGylation of therapeutic proteins., Curr Opin Drug Discov Devel, 11, 242

Pan, 2006, Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist., J Biol Chem, 281, 12506, 10.1074/jbc.M600127200

Junutula, 2008, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index., Nat Biotech, 26, 925, 10.1038/nbt.1480

Lenting, 2007, Clearance mechanisms of von Willebrand factor and factor VIII., J Thromb Haemost, 5, 1353, 10.1111/j.1538-7836.2007.02572.x